1. Br J Surg. 2023 Jul 17;110(8):931-935. doi: 10.1093/bjs/znac424.

Resectability and resection rates of colorectal liver metastases according to 
RAS and BRAF mutational status: prospective study.

Uutela A(1)(2), Nordin A(1), Osterlund E(1)(3), Halonen P(4), Kallio R(5), 
Soveri LM(6)(7), Salminen T(8), Ålgars A(9), Ristimäki A(10), Ovissi A(11), 
Lamminmäki A(12), Muhonen T(7)(13), Kononen J(14)(15), Ristamäki R(9), Heervä 
E(9), Stedt H(12), Lehtomäki K(8), Kytölä S(16), Sundström J(17), Mäkinen 
MJ(18), Nieminen L(19), Kuopio T(20), Keinänen M(21), Osterlund P(4)(8)(22), 
Isoniemi H(1); RAXO Study Group.

Collaborators: Mäkisalo H, Huuhtanen R, Lantto E, Kosunen J, Leppä S, Bono P, 
Mattson J, Räsänen J, Lepistö A, Penttinen H, Mäkelä S, Carpén O, Lundbom N, 
Hakkarainen A, Timonen M, Salminen V, Paunu N, Rinta-Kiikka I, Vornanen M, 
Virtanen J, Korkeila E, Sutinen E, Lavonius M, Sundström J, Blanco R, Pääkkö E, 
Tuomisto-Huttunen T, Auvinen P, Kärjä V, Kainulainen S, Kettunen HP, Kellokumpu 
I, Aarnio M, Väyrynen V, Vasala K, Ketola S, Nuorva K, Murashev ML, Pulkkanen K, 
Viitanen V, Nieppola M, Haalisto E, Nyandoto P, Aalto A, Ala-Luhtala T, 
Tuominiemi J, Sainast A, Pusa L, Kosonen S, Helle L, Hermansson T, Kokko R, 
Aroviita L, Nokisalmi P, Sailas L, Tokola H, Jekunen A, Pöytäkangas T, Möykkynen 
K, Kosonen S, Isokangas OP, Vaarala S, Klaavuniemi T, Kolle R, Karihtala P, 
Heikkinen M, Johansson K, Sjöstrand A, Kajasviita P, Kaleva-Kerola J, Männistö 
E, Lindvall-Andersson R, Kaunismaa T, Vihinen P, Cavalli-Björkman N.

Author information:
(1)Department of Transplantation and Liver Surgery, Abdominal Centre, Helsinki 
University Hospital and University of Helsinki, Helsinki, Finland.
(2)Department of Transplant and Hepatopancreatobiliary Surgery, Royal Infirmary 
of Edinburgh, Edinburgh, UK.
(3)Department of Immunology, Genetics and Pathology, Uppsala University, 
Uppsala, Sweden.
(4)Department of Oncology, Helsinki University Hospital Comprehensive Cancer 
Centre and University of Helsinki, Helsinki, Finland.
(5)Department of Oncology, Oulu University Hospital, Oulu, Finland.
(6)Home Care Geriatric Clinic and Palliative Care, Joint Municipal Authority for 
Health Care and Social Services in Keski-Uusimaa, Hyvinkää, Finland.
(7)Faculty of Medicine, University of Helsinki, Helsinki, Finland.
(8)Department of Oncology, Tampere University Hospital and University of 
Tampere, Tampere, Finland.
(9)Department of Oncology, Turku University Hospital and University of Turku, 
Turku, Finland.
(10)Department of Pathology, HUS Diagnostic Centre and Applied Tumour Genomics, 
Research Programmes Unit, Helsinki University Hospital and University of 
Helsinki, Helsinki, Finland.
(11)Department of Radiology, HUS Medical Imaging Centre, Helsinki University 
Hospital and University of Helsinki, Helsinki, Finland.
(12)Department of Oncology, Kuopio University Hospital and University of Eastern 
Finland, Kuopio, Finland.
(13)Department of Oncology, South Carelia Central Hospital, Lappeenranta, 
Finland.
(14)Department of Oncology, Central Finland Hospital Nova, Jyväskylä, Finland.
(15)Docrates Cancer Center, Helsinki, Finland.
(16)Department of Genetics, HUSLAB, HUS Diagnostic Centre, Helsinki University 
Hospital and University of Helsinki, Helsinki, Finland.
(17)Department of Pathology, Turku University Hospital and University of Turku, 
Turku, Finland.
(18)Department of Pathology, Oulu University Hospital and University of Oulu, 
Oulu, Finland.
(19)Department of Pathology, Tampere University Hospital and University of 
Tampere, Tampere, Finland.
(20)Department of Pathology, Central Finland Central Hospital, Jyväskylä, 
Finland.
(21)Department of Genetics, FIMLAB laboratories, Tampere University Hospital, 
Tampere, Finland.
(22)Department of Oncology/Pathology, Karolinska Institutet and Karolinska 
Sjukhuset, Cancer Centre of Excellence, Stockholm, Sweden.

DOI: 10.1093/bjs/znac424
PMCID: PMC10361677
PMID: 36511370 [Indexed for MEDLINE]